Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
This scheme has maintained a relatively low level of volatility within its Dynamic Asset Allocation category over the past 3 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback